Passa al contenuto
Merck
  • Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.

Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.

Antimicrobial agents and chemotherapy (2008-07-16)
Jan Paeshuyse, Inge Vliegen, Lotte Coelmont, Pieter Leyssen, Oriana Tabarrini, Piet Herdewijn, Harald Mittendorfer, Johnny Easmon, Violetta Cecchetti, Ralf Bartenschlager, Gerhard Puerstinger, Johan Neyts
ABSTRACT

We report here a comparative study of the anti-hepatitis C virus (HCV) activities of selected (i) nucleoside polymerase, (ii) nonnucleoside polymerase, (iii) alpha,gamma-diketo acid polymerase, (iv) NS3 protease, and (v) helicase inhibitors, as well as (vi) cyclophilin binding molecules and (vii) alpha 2b interferon in four different HCV genotype 1b replicon systems.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Cyclosporin A, 97.0-101.5% (on dried basis)
Sigma-Aldrich
Cyclosporin A, from Tolypocladium inflatum, ≥95% (HPLC), solid
Sigma-Aldrich
Cyclosporin A, from Tolypocladium inflatum, BioReagent, for molecular biology, ≥95%
Sigma-Aldrich
2-Thiophenecarboxylic acid, ReagentPlus®, 99%
Supelco
Cyclosporin A, VETRANAL®, analytical standard